University of Iowa Research Foundation

Alcon, Inc.

Other

Edwin M Stone

Val C Sheffield

Darryl Nishimura

Wallace L M Alward

John Fingert

Wallace L Alward

Shiva Patil

Abbot F Clark

Wan-Heng Wang

Loretta Graves McNatt

Kirk Mykytyn

Charles C Searby

Thomas L Casavant

Kent W Small

Terry Braun

Brian E Nichols

The present invention relates to compositions and methods for treating, screening and diagnosing macular degeneration in a subject. This is a new pathway found which is the only one known to be involved in development of the human macula. Manipulation and control of this pathway will allow rebuilding and/or repair of the macula, making new and improved better maculae.

Methods for treating macular degeneration

The present invention relates to the identification of a gene, now designated negevin (ngvn), that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. The human NGVN protein disclosed herein is 731 amino acids in length and is coded for by a gene spanning 17 exons. Homologs have been identified in mouse, rat, zebrafish. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Bardet-Biedl susceptibility gene and uses thereof

Methods and compositions for diagnosing and treating glaucoma are disclosed.

Diagnostics and therapeutics for glaucoma

The present invention relates to the designation of ADP-ribosylation factor-like 6 as the BBS3 gene, that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

The present invention relates to the identification of a gene, now designated BBS4, that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. The human BBS4 protein disclosed herein is 519 amino acids in length and is coded for by a gene spanning 16 exons. Homologs have been identified in mouse, rat, zebrafish. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Bardet-biedl susceptibility gene and uses thereof

The present invention relates to the identification of a gene, mutated at the most common locus now designated BBS1, that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypogonadism, mental retardation, renal cancer and other renal abnormalities, retinopathy and polydactyly or limb deformities. The human BBS1 protein disclosed herein is composed of 17 exons and spans approximately 23 kb. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Identification of a gene causing the most common form of bardet-biedl syndrome and uses thereof

Methods and compositions for preventing and treating glaucoma; and glaucoma diagnostics are disclosed.

Glaucoma therapeutics and diagnostics

Methods and compositions for treating a congenital heart disease and methods and compositions for prognosing or diagnosing a congenital heart disease in a subject are disclosed.

Methods to identify modulators of FKHL7 DNA-binding activity

Therapeutics and diagnostics based on the identification of genetic mutations, which cause Macular Degeneration (MD) are disclosed.

Macular degeneration diagnostics and therapeutics

Therapeutics and diagnostics based on the identification of genetic mutations, which cause Macular Degeneration (MD) is disclosed.

Glaucoma compositions comprising the GLC1A gene are disclosed.

Growing community of inventors

Iowa City, IA, United States of America

Edwin M Stone